P511. Epstein-Barr Virus in inflammatory bowel disease – correlation with different therapeutic regimens
F. Magro1, J. Santos-Antunes1, A. Albuquerque1, F. Vilas-Boas1, G.N. Macedo2, N. Nazareth2, S. Lopes1, J. Sobrinho-Simões3, S. Teixeira3, C. Camila-Dias4, J. Cabral5, A. Sarmento2, G. Macedo1, 1Centro Hospitalar S. João, Gastroenterology, Porto, Portugal, 2CEBIMED – Biomedicine Research Center, Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal, 3Centro Hospitalar S. João, Clinical Pathology Department, Porto, Portugal, 4Faculty of Medicine, University of Porto, CIDES – Department of Health Information and Decision Sciences, Porto, Portugal, 5Faculty of Medicine, University of Porto, Institute of Pharmacology and Therapeutics, Porto, Portugal
Epstein-Barr Virus (EBV) is a ubiquitous virus related to several malignancies, namely lymphoma; its prevalence in IBD patients and its relation with different therapeutic regimens are not well studied.
Patients were consecutively enrolled for participation, and healthy volunteers were recruited as controls. EBV-DNA was measured at least one time in each patient.
Three hundred and seventy nine individuals were enrolled (93 treated with 5-Aminosalicylates, 91 with Azathioprine, 70 with Infliximab, 43 with combined treatment with Infliximab and Azathioprine, and 82 controls). More than 90% of the patients had previous EBV exposure. EBV-DNA was found in 132 samples (35%); its prevalence was significantly higher in every group of IBD patients, comparing to controls. Among IBD patients, Infliximab (with or without Azathioprine) was related to higher prevalence of EBV comparing to Azathioprine alone or 5-Aminosalicylates (p < 0.05). Age above 60 years was related to EBV-DNA positivity with a specificity of 92%. Concerning treated groups, Ulcerative Colitis was the only risk factor identified for high levels of EBV-DNA (>1000 and 2500 copies/mL). No relation was found between EBV and C-reactive protein.
IBD is a risk factor for the presence of EBV-DNA in blood, mainly in older patients and in those taking Infliximab. C-reactive protein was not related to EBV DNA prevalence.